Study design and participants
RECRUITMENT, RECRUITMENT
This was a double-blind, parallel-arm, randomised controlled trial investigating the efficacy of PCV13 or placebo (1:1) against experimental pneumococcal carriage of The trial was approved in Malawi by the National Health Sciences Research Committee (16/07/2519) and Pharmacy Medicines and Regulatory Authority (PMRA/CTRC/III/10062020121) and in the UK by the Liverpool School of Tropical Medicine (20-021). Written informed consent was obtained for all participants.Healthy adult participants were recruited from the community, workplaces, and colleges in Blantyre, Malawi. Study procedures took place in the Ward 3A research clinic, Queen Elizabeth Central Hospital (Blantyre, Malawi). Recruitment commenced on April 27, 2021 and the final visit was completed on Sept 12, 2022. A detailed description of screening, eligibility and recruitment procedures is described elsewhere.